ClinicalTrials.gg

Program

Multivalent Group B streptococcus vaccine

Also written as “Multivalent group B streptococcus vaccine”.

Its studies are mostly in Streptococcal Infections, led by Pfizer.

Furthest: phase 3, since Aug 14, 20254 company-led studies, 1 open or runningNext primary completion: Nov 6, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer41 open or runningphase 3since Aug 14, 2025May 26, 2017Nov 6, 2028phase 3 · NCT07160244

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 26, 2017First study: phase 2 study in Streptococcal InfectionsFirst studyNCT03170609 · 365 enrolled · United States
  2. Dec 4, 2018Phase 2 study in Group B Streptococcus InfectionsNCT03765073 · 1,208 enrolled · United States, South Africa, United Kingdom
  3. Feb 18, 2021Phase 2 study in Group B Streptococcus InfectionsNCT04766086 · 306 enrolled · United States
  4. Aug 14, 2025Phase 3 study in HealthyNCT07160244 · 6,000 planned · United States, Argentina, Brazil and more

Ahead

  1. Nov 6, 2028Primary completion: phase 3 study in HealthyNCT07160244

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Multivalent Group B streptococcus vaccine”name, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07160244Healthy · United States, Argentina, Brazil and more3RecruitingNov 6, 20286,000
NCT04766086Group B Streptococcus Infections · United States2CompletedApr 27, 2023306
NCT03765073Group B Streptococcus Infections · United States, South Africa, United Kingdom2CompletedMar 4, 20241,208
NCT03170609Streptococcal Infections · United States2CompletedJun 25, 2018365

How it is read

Names in the registry

  • “Multivalent Group B streptococcus vaccine”, 3 entries
  • “Multivalent group B streptococcus vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.